Home > Drugs A – Z > Fondaparinux (By injection)

Fondaparinux (By injection)

Treats blood clots and prevents them from forming after hip, knee, or stomach surgery. This medicine is a blood thinner.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Fondaparinux is used to prevent deep vein thrombosis, a condition in which harmful blood clots form in the blood vessels of the legs. These blood clots can travel to the lungs and can become lodged in the blood vessels of the lungs, causing a condition called pulmonary embolism. This medicine is used for several days after hip fracture surgery, hip or knee replacement surgery, and in some cases… Read more
Brand names include
Arixtra
Drug classes About this
Anticoagulant

What works? Research summarized

Evidence reviews

Fondaparinux versus Enoxaparin for Acute Coronary Syndrome: A Review of the Comparative Clinical Effectiveness and Cost-Effectiveness [Internet]

Fondaparinux may offer both advantages and disadvantages when compared to older anticoagulants, such as enoxaparin. It is therefore important, in clinical practice, to assess the risk-benefit profile when determining which anticoagulant agent should be prescribed to patients. This should include considerations on both the clinical and economic evidence. The purpose of this review is therefore to compare the available evidence on fondaparinux to enoxaparin on patient with ACS in terms of their clinical effectiveness, safety and cost-effectiveness.

Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux

Bibliographic details: Loffredo L, Perri L, Catasca E, Del Ben M, Angelico F, Violi F.  Antithrombotic drugs in acutely ill medical patients: review and meta-analysis of interventional trials with low-molecular-weight heparin and fondaparinux. Clinical Practice 2013; 10(5): 615-627

[Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis]

OBJECTIVE: To systematically review the efficacy and safety of fondaparinux and enoxaparin in the prevention of venous thromboembolism (VTE) after major orthopedic surgery.

See all (47)

Summaries for consumers

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip: A Review of the Research for Adults

This summary covers what research says about the possible benefits and side effects of treatments to help prevent a blood clot after hip or knee surgery. Treatment options include medicines that thin your blood and devices that increase blood flow in your legs (leg or foot coverings that inflate and deflate or elastic stockings). This summary can help you discuss these options with your doctor.

Factor Xa inhibitors for acute coronary syndromes

The use of unfractionated heparin and low molecular weight heparins greatly reduces the risk of mortality and morbidity in acute coronary syndromes. However, their use has been associated with a risk of adverse events such as major bleeding, which has prompted researchers to seek safer alternative anticoagulants such as the synthetic inhibitors of the Xa factor ‐ a crucial enzyme in the coagulation cascade. We systematically reviewed efficacy and safety of factor Xa inhibitors in treating acute coronary syndromes when compared to unfractionated heparins or low molecular weight heparins. A total of four trials involving 27,976 subjects was included. Xa inhibitors reduced all‐cause mortality at 30 days, with the effect becoming more significant at 180 days. However, no significant differences were observed in the incidence of myocardial infarction or reinfarction at 30 days. Factor Xa inhibitors were found to be safer than enoxaparin, a low molecular weight heparin, due to reduced incidences of major and minor bleeding at 30 patients in patients receiving conservative treatment.

Treatment for superficial thrombophlebitis of the leg

Superficial thrombophlebitis (ST) is a relatively common inflammatory process associated with a blood clot (thrombus) that affects the superficial veins (veins that are close to the surface of the body). Symptoms and signs include local pain, itching, tenderness, reddening of the skin, and hardening of the surrounding tissue. There is some evidence to suggest a link between ST and venous thromboembolism (VTE; a condition where blood clots form (most often) in the deep veins of the leg and can travel in the circulation and lodge in the lungs). Treatment aims to relieve the local symptoms and to prevent the extension of the clot into a deep vein, ST recurrence, or the development of more serious events caused by VTE. This is the third update of a review first published in 2007. The evidence is current to March 2017.

See all (13)

PubMed Health Blog...

read all...